Tonix Pharmaceuticals stock halted ahead of FDA approval news
On Tuesday, Goldman Sachs initiated coverage on Viking Therapeutics (NASDAQ:VKTX) with a Neutral rating and a price target of $30.00. The stock, currently trading at $21.28, has experienced significant pressure, declining over 70% in the past year. According to InvestingPro data, Viking maintains a strong financial position with more cash than debt on its balance sheet. The firm's analysis pointed to the competitive nature of the obesity treatment market as a significant challenge for Viking's lead asset, VK2735. The therapy, a dual GLP-1/GIP agonist, has shown promise in Phase 2 trials, demonstrating potency and safety. However, Goldman Sachs highlighted the high barriers to entry in the obesity market, such as price erosion, payer restrictions, and the need for rebates to pharmacy benefit managers (PBMs).
The Goldman Sachs report underscored that VK2735 might face disadvantages without clinical evidence of additional health benefits, unlike many competitors that have shown or are developing treatments for type 2 diabetes (T2D), cardiovascular, renal, and liver benefits. The crowded market, with many next-generation therapies on the horizon, could pose further difficulties for Viking Therapeutics, especially as a smaller entity with fewer resources. With a market capitalization of $2.39 billion and an overall "FAIR" financial health score from InvestingPro, the company faces both opportunities and challenges in this competitive landscape.
Goldman Sachs' neutral stance is influenced by the projected risk-adjusted peak sales for VK2735, which they estimate at $2.8 billion compared to the consensus of $9.2 billion. This conservative forecast reflects the firm's cautious outlook on Viking Therapeutics' potential to secure a significant share in the obesity drug market.
As Viking Therapeutics navigates the challenges of a hyper-competitive landscape, Goldman Sachs' assessment suggests that the company's success may hinge on its ability to differentiate VK2735 and overcome the market's high entry barriers. With the price target set at $30.00, investors now have a benchmark against which to measure Viking Therapeutics' progress in the coming months and years. Notably, analyst targets range from $38 to $164, reflecting diverse views on the company's potential. For deeper insights into Viking's valuation and growth prospects, including 14 additional ProTips and comprehensive financial analysis, explore the detailed research available on InvestingPro.
In other recent news, Viking Therapeutics has announced a strategic manufacturing agreement with CordenPharma to ensure a steady supply of its obesity treatment, VK2735. This deal includes the production of the drug's active pharmaceutical ingredient and various product forms, preparing for a potential multi-billion-dollar market opportunity. Viking will prepay $150 million between 2025 and 2028 to secure these production capabilities. In terms of clinical developments, Viking has completed enrollment for the Phase 2 VENTURE-Oral trial of VK2735, which aims to assess the drug's efficacy in weight loss over 13 weeks. Looking ahead, the company plans to enter Phase 3 trials for the subcutaneous form of VK2735 in 2025. H.C. Wainwright reaffirmed its Buy rating and $102 price target for Viking Therapeutics, citing confidence in VK2735's potential. Conversely, Citi analysts initiated coverage with a Neutral rating and a $38 price target, highlighting the competitive nature of the obesity treatment market and the need for more safety data. These developments reflect the company's ongoing efforts to position VK2735 as a significant player in the metabolic disease treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.